Mechanism of BRAF Inhibitor Resistance

This research aims to elucidate the underlying mechanisms responsible for the variable efficacy of Dabrafenib, a potent inhibitor of the BRAF V600E mutation, across diverse cancer type. Our unbiased, bioinformatics-driven methodology has shed light on the mechanisms that elevated PIK3CG expression contributing to Dabrafenib resistance. These insights pave the way for the development of novel strategies to address BRAF inhibitor resistant cancers.

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)